Benjamin Engelhardt - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Benjamin Engelhardt

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Clinical Therapeutics|October 5, 2024

Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response RelationshipsMohamed Badawi, Sathej Gopalakrishnan, Benjamin Engelhardt, et al.

Hematological Oncology|September 23, 2023

Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.

Clinical and Translational Science|August 10, 2020

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Clinical Therapeutics|October 5, 2024

Hematological Oncology|September 23, 2023

Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.

Clinical and Translational Science|August 10, 2020

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.

Pageof 2